CalcMyPeptide
MitochondrialAlso known as: Elamipretide, Bendavia, MTP-131

SS-31

SS-31 (Elamipretide) is a cellular rescue tetrapeptide designed to halt horrific mitochondrial collapse during aging or acute ischemic injury. Unlike conventional antioxidants that indiscriminately scavenge free radicals, SS-31 acts as structural scaffolding inside the mitochondria. It is utilized in advanced anti-aging stacks to completely reverse age-related declines in ATP (energy) production, restore muscular endurance, and prevent catastrophic tissue damage following heart attacks or organ ischemia.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Moderate3 peer-reviewed citations

Quick Stats

Half-Life~4-5 hours
Dose Range20-40 mg/day (clinical trials)
Frequency1× daily
Vial Sizes5 mg
Bioavailability~100% (subcutaneous)
Year Developed2002

Scientific Data

Molecular Formula
C32H52N10O8
Molecular Weight
736.83 g/mol
CAS Number
PubChem ID
Developer
Hazel Szeto, Weill Cornell Medical College

Mechanism of Action

SS-31 (Elamipretide, Bendavia) is a mitochondria-targeting tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds to cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for electron transport chain function — when it becomes oxidized with age, mitochondrial efficiency declines. SS-31 prevents cardiolipin peroxidation, restoring mitochondrial bioenergetics.

SS-31 is unique among peptides in that it concentrates 1000-5000× in mitochondria versus the extracellular space. It is in clinical trials for Barth syndrome, age-related macular degeneration, and primary mitochondrial myopathy.

Source: PMID: 26857943

Background & History

SS-31 (Elamipretide, MTP-131) is a tetrapeptide targeting cardiolipin — a phospholipid exclusively located in the inner mitochondrial membrane critical for electron transport chain function. Developed by Hazel Szeto at Weill Cornell Medical College in the 2000s, SS-31 penetrates the inner mitochondrial membrane (unique for a water-soluble peptide) and protects cardiolipin from oxidative damage. Clinical trials have evaluated it in heart failure (BENEFIT-HF), kidney disease, and Barth syndrome. It is the most clinically advanced mitochondria-targeted therapeutic peptide.

Research Use Cases

  • Heart failure and cardiac function improvement
  • Acute kidney injury protection and recovery
  • Reducing mitochondrial oxidative stress in aging tissues
  • Skeletal muscle energetics in mitochondrial myopathies
  • Ischemia-reperfusion injury protection (surgery, stroke, heart attack)

Dosing Protocol

Typical Dose20-40 mg/day (clinical trials)
Frequency1× daily
Half-Life~4 hours
Common Vial Sizes5 mg

Dosing Protocols

Research Protocol

Dose
0.1 - 0.25 mg/kg
Frequency
Daily or 5x weekly (SC)
Note: Concentrates 1000-5000x in mitochondria. Clinical trials ongoing for Barth syndrome and AMD.

Administration

Route
Subcutaneous injection
Timing
Morning. Fasting not required.
Fasting Required?
No — food timing not critical

Expected Timeline

Week 1-4
Improved cellular energy. Reduced oxidative stress markers.
Month 1-3
Functional improvements in mitochondrial disease models. Exercise capacity improvements.

Who Is It For?

Mitochondrial Dysfunction

High

Directly targets inner mitochondrial membrane cardiolipin. In clinical trials for primary mitochondrial diseases.

Longevity / Anti-Aging

Moderate

Restores age-associated mitochondrial bioenergetic decline.

Reconstitution Example

Vial
5 mg
Water
2 mL
Concentration
2.5 mg/mL
Per Unit (100u syringe)
25 mcg
Dose of 20000 mcg = 800 units on a 100-unit insulin syringe

Safety & Considerations

Investigational drug in active clinical trials. Not FDA-approved. Generally well-tolerated. Injection site reactions are the most common adverse event.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

No significant drug interactions identified in clinical trials to date. SubQ injection required — oral bioavailability negligible. Investigational — not approved for clinical use outside of trials.

Synergies & Common Stacks

Complementary mitochondrial protection: SS-31 protects the inner membrane and electron transport chain; MOTS-c activates AMPK metabolic signaling. Together address both structural and functional mitochondrial health.

NAD+ supports NADH/NAD+ cycling; SS-31 protects the complexes that use NADH. Additive protection of the electron transport chain.

Dosing Quick Reference

SS-31— Dosing Guide
Dose Range
20-40 mg/day (clinical trials)
Half-Life
~4 hours
Frequency
1× daily
Route
Subcutaneous
5 mg vial
💧 2 mL BAC water📐 2.5 mg/mL concentration💉 25 mcg/unit (100u syringe)
Mitochondrialcalcmypeptide.com

Frequently Asked Questions

What is SS-31 used for?
SS-31 (Elamipretide) targets the inner mitochondrial membrane to restore bioenergetics. In clinical trials for Barth syndrome, primary mitochondrial myopathy, and age-related macular degeneration.
How does SS-31 differ from MOTS-c?
SS-31 concentrates directly in mitochondria (1000-5000x) by binding cardiolipin. MOTS-c acts via AMPK signaling. Fundamentally different mechanisms — sometimes combined.

References

  1. Szeto HH "Elamipretide (SS-31) improves mitochondrial dysfunction and muscle function".” Journal of Bioenergetics and Biomembranes (2013). PMID: 24337793

📚 Related Articles

Recommended Source10% OFF

Get SS-31 from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Affiliate link · Full review